Skip to content
Subscriber Only

Eisai May Start Skin-Patch Aricept U.S. Sales in 2011

Eisai Co. plans to introduce a skin-patch version of the Aricept Alzheimer’s disease treatment in the U.S. as early as the second quarter of next year to help buffer an anticipated decline in sales of its biggest drug.

Teikoku Seiyaku Co., Eisai’s development partner, submitted patient-trial data to the U.S. Food and Drug Administration on June 30, Lynn Kramer, head of neuroscience product development at the Tokyo-based company, said on a conference call today. The regulator typically takes 10 months to complete a review.